meta
|
evidence
oncology
Living systematic review and meta-analysis
castration-resistant prostate cancer (CRPC)
metastatic (mCRPC) - 1st line (L1)
3
metastatic (mCRPC) - 2nd line (L2)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
nivolumab based treatment
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab plus enzalutamide
Immune checkpoint association
durvalumab plus tremelimumab
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
no study with result for this clinical condition